Consolidated total revenue from operations of the company stood at Rs 4,011.90 crore for the quarter under consideration. It was Rs 4,082.41 crore for the same period a year ago.
"We had a modest quarter but maintained a strong performance in our private market segment across geographies.
The company also recently announced the approval of Metoprolol, another limited competition asset, he added.
"As we enter the second half of this fiscal, multiple headwinds are likely to impact our reported performance. Having said that, we are focusing on positioning our businesses for long term growth," Vohra added.
Shares of Cipla were Monday trading at Rs 566.10 on the BSE, down by 6.97 per cent from their previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)